164 related articles for article (PubMed ID: 16807234)
1. BRCA1 suppresses osteopontin-mediated breast cancer.
El-Tanani MK; Campbell FC; Crowe P; Erwin P; Harkin DP; Pharoah P; Ponder B; Rudland PS
J Biol Chem; 2006 Sep; 281(36):26587-601. PubMed ID: 16807234
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.
El-Tanani MK; Yuen HF; Shi Z; Platt-Higgins A; Buckley NE; Mullan PB; Harkin DP; Johnston PG; Rudland PS
Cancer Sci; 2010 Jun; 101(6):1354-60. PubMed ID: 20384635
[TBL] [Abstract][Full Text] [Related]
3. Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription.
El-Tanani M; Platt-Higgins A; Rudland PS; Campbell FC
J Biol Chem; 2004 May; 279(20):20794-806. PubMed ID: 14990565
[TBL] [Abstract][Full Text] [Related]
4. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.
Beausoleil MS; Schulze EB; Goodale D; Postenka CO; Allan AL
BMC Cancer; 2011 Jan; 11():25. PubMed ID: 21247495
[TBL] [Abstract][Full Text] [Related]
5. Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression.
El-Tanani MK; Jin D; Campbell FC; Johnston PG
Oncogene; 2010 Feb; 29(5):752-62. PubMed ID: 19901966
[TBL] [Abstract][Full Text] [Related]
6. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells.
Ahmed M; Kundu GC
Mol Cancer; 2010 May; 9():101. PubMed ID: 20459645
[TBL] [Abstract][Full Text] [Related]
8. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin.
Kurisetty VV; Johnston PG; Johnston N; Erwin P; Crowe P; Fernig DG; Campbell FC; Anderson IP; Rudland PS; El-Tanani MK
Oncogene; 2008 Dec; 27(57):7139-49. PubMed ID: 18794800
[TBL] [Abstract][Full Text] [Related]
9. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
Ma Y; Katiyar P; Jones LP; Fan S; Zhang Y; Furth PA; Rosen EM
Mol Endocrinol; 2006 Jan; 20(1):14-34. PubMed ID: 16109739
[TBL] [Abstract][Full Text] [Related]
10. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
11. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts.
Suzuki M; Mose E; Galloy C; Tarin D
Am J Pathol; 2007 Aug; 171(2):682-92. PubMed ID: 17620367
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of osteopontin attenuates breast tumour progression in vivo.
Chakraborty G; Jain S; Patil TV; Kundu GC
J Cell Mol Med; 2008 Dec; 12(6A):2305-18. PubMed ID: 18266970
[TBL] [Abstract][Full Text] [Related]
14. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Kawai H; Li H; Chun P; Avraham S; Avraham HK
Oncogene; 2002 Oct; 21(50):7730-9. PubMed ID: 12400015
[TBL] [Abstract][Full Text] [Related]
15. S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.
Buckley NE; D'Costa Z; Kaminska M; Mullan PB
Cell Death Dis; 2014 Feb; 5(2):e1070. PubMed ID: 24556685
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
Raja R; Kale S; Thorat D; Soundararajan G; Lohite K; Mane A; Karnik S; Kundu GC
Oncogene; 2014 Apr; 33(16):2053-64. PubMed ID: 23728336
[TBL] [Abstract][Full Text] [Related]
17. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
Bowman-Colin C; Xia B; Bunting S; Klijn C; Drost R; Bouwman P; Fineman L; Chen X; Culhane AC; Cai H; Rodig SJ; Bronson RT; Jonkers J; Nussenzweig A; Kanellopoulou C; Livingston DM
Proc Natl Acad Sci U S A; 2013 May; 110(21):8632-7. PubMed ID: 23657012
[TBL] [Abstract][Full Text] [Related]
18. A transcriptional repressor of osteopontin expression in the 4T1 murine breast cancer cell line.
Gao C; Mi Z; Guo H; Wei J; Wai PY; Kuo PC
Biochem Biophys Res Commun; 2004 Sep; 321(4):1010-6. PubMed ID: 15358129
[TBL] [Abstract][Full Text] [Related]
19. BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR.
Hao L; ElShamy WM
Int J Cancer; 2007 Jul; 121(1):39-46. PubMed ID: 17278098
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin regulates ubiquitin-dependent degradation of Stat1 in murine mammary epithelial tumor cells.
Gao C; Mi Z; Guo H; Kuo PC
Neoplasia; 2007 Sep; 9(9):699-706. PubMed ID: 17898865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
